67 results
Page 2 of 4
424B5
5tw34w2105eqmq sl
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
ummq8h cvlqt90dq1ox
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
ta56t 6kevuo8w
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
sdvi72jy
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
nd0 6l9i8njmxdk
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
424B4
34zjoe8a3fdvtc9c 6d
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-10.1
56hzdm7e 7izdbq7w
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
pzm7l7cbw7mhss4t
20 Aug 20
Entry into a Material Definitive Agreement
9:30am